The net profit (consolidated) of Ranbaxy Laboratories jumped to Rs.312.80 crore during the quarter ended September 30, 2010, from Rs.116.60 crore in the same period last fiscal on the back of surge in sales in the U.S. market.
The company also benefited from favourable forex movement in the third quarter, the company said in a statement here.
“Our key markets continued to perform well attributable in large measure to balanced sales across geographies. This has also been aided by favourable forex movement,” Ranbaxy Managing Director Arun Sawhney said.
The company's total operating income rose to Rs.1,934.60 crore during the quarter from Rs.1,885.80 crore in the corresponding period last fiscal.
During the quarter, the company posted sales of Rs.491.20 crore in the North American region, an increase of over 70 per cent, on the back of robust sales of Valacyclovir, which continued to enjoy a healthy market share of 36 per cent, even after losing exclusivity for the drug. The company's domestic sales stood at Rs.493 crore for the third quarter, while CIS region's sales stood at Rs.120.90 crore.
The company's sales stood at Rs.164.40 crore in Africa. Its active pharmaceutical ingredient (API) business posted sales of Rs.108.20 crore in the quarter.
In Europe, the company posted sales of Rs.276.90 crore during the said quarter.
The company said it will continue to maximise synergies with its parent, Daiichi Sankyo that holds 64 per cent in the company.